Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dapagliflozin has No Protective Effect on Experimental Pulmonary Arterial Hypertension and Pulmonary Trunk Banding Rat Models
Huayang Li, Yitao Zhang, Shunjun Wang, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 18

Showing 18 citing articles:

Canagliflozin inhibits PASMCs proliferation via regulating SGLT1/AMPK signaling and attenuates artery remodeling in MCT-induced pulmonary arterial hypertension
X.H. Chen, Xing Yu, Guili Lian, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116505-116505
Open Access | Times Cited: 7
Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension
Yi Tang, Siyuan Tan, Minqi Li, et al.
BMC Pulmonary Medicine (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 25
Molecular mechanisms and targets of right ventricular fibrosis in pulmonary hypertension
Fjodor Bekedam, Marie‐José Goumans, Harm Jan Bogaard, et al.
Pharmacology & Therapeutics (2023) Vol. 244, pp. 108389-108389
Open Access | Times Cited: 14
The right ventricle in tetralogy of Fallot: adaptation to sequential loading
Rahi S. Alipour Symakani, Wouter J. van Genuchten, Lotte Zandbergen, et al.
Frontiers in Pediatrics (2023) Vol. 11
Open Access | Times Cited: 13
Canagliflozin alleviates pulmonary hypertension by activating PPARγ and inhibiting its S225 phosphorylation
Xiuchun Li, Xiayan Zhu, Yangyue Wang, et al.
Acta Pharmacologica Sinica (2024) Vol. 45, Iss. 9, pp. 1861-1878
Open Access | Times Cited: 4
SGLT2 inhibitors as a potential therapeutic option for pulmonary hypertension: mechanisms and clinical perspectives
Jiang-Shan Tan, Yixiao Wei, Lingtao Chong, et al.
Critical Reviews in Clinical Laboratory Sciences (2024), pp. 1-17
Closed Access | Times Cited: 3
Effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors, dapagliflozin and canagliflozin, on the musculoskeletal system in an experimental model of diabetes induced by high-fat diet and streptozotocin in rats
Piotr Londzin, Maria Zych, Aleksandra Janas, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 184, pp. 117912-117912
Open Access
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
Munteanu Madalina Andreea, Swarnkar Surabhi, Răzvan-Ionuț Popescu, et al.
Medicina (2023) Vol. 59, Iss. 4, pp. 742-742
Open Access | Times Cited: 9
Dapagliflozin alleviates right heart failure by promoting collagen degradation by reducing ROS levels
Dongdong Liu, Xiaolin Liu, Tengfei Zheng, et al.
European Journal of Pharmacology (2024) Vol. 981, pp. 176875-176875
Closed Access | Times Cited: 2
Effects of empagliflozin on right ventricular adaptation to pressure overload
Julie Birkmose Axelsen, Anders Hammer Nielsen-Kudsk, Janne Schwab, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 6
Unfavorable effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on the skeletal system of nondiabetic rats
Piotr Londzin, Agata Brudnowska, Katarzyna Kurkowska, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 155, pp. 113679-113679
Open Access | Times Cited: 8
Therapeutic Approaches in Pulmonary Arterial Hypertension with Beneficial Effects on Right Ventricular Function – Preclinical Studies
André Balsa, Rui Adão, Carmen Brás‐Silva
(2023)
Open Access | Times Cited: 4
Therapeutic Approaches in Pulmonary Arterial Hypertension with Beneficial Effects on Right Ventricular Function—Preclinical Studies
André Balsa, Rui Adão, Carmen Brás‐Silva
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 21, pp. 15539-15539
Open Access | Times Cited: 4
Changes of Pulmonary Microhemodynamics in Experimental Pulmonary Thromboembolism after Pretreatment with K-Channel Activators
В. И. Евлахов, I. Z. Poyasov, Т. П. Березина
Bulletin of Experimental Biology and Medicine (2022) Vol. 173, Iss. 3, pp. 302-305
Closed Access | Times Cited: 6
Role of subpulmonary right ventricle in sudden cardiac death in adults with congenital heart disease
Satoshi Kawada, Praloy Chakraborty, Jayant Kakarla, et al.
Heart Rhythm (2024)
Closed Access
Canagliflozin alleviates pulmonary hypertension partially by inhibition of PPARγ S225 phosphorylation and PPARγ-mediated suppression of oxidative stress
Xiaoying Huang, Xiuchun Li, Lanlan Song, et al.
Research Square (Research Square) (2023)
Open Access | Times Cited: 1
Glycolysis in pulmonary arterial hypertension and metabolic reprogramming
Inês Vasconcelos, Francisco Pérez‐Vizcaíno, Adelino Leite‐Moreira, et al.
Elsevier eBooks (2023), pp. 267-296
Closed Access
Canagliflozin inhibits PASMCs proliferation via regulating SGLT1/AMPK signaling and attenuates vascular remodeling in MCT-induced pulmonary arterial hypertension
Xiaojun Chen, Xing Yu, Guili Lian, et al.
Research Square (Research Square) (2023)
Open Access
Page 1

Scroll to top